Synapse - Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis

Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis Meeting Abstract

Authors:	Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; Hassoun, H.; Tan, C.; Hultcrantz, M.; Shah, G.; Landau, H.; Chung, D.; Scordo, M.; Dogan, A.; Giralt, S.; Rivière, I.; Brentjens, R.; Smith, E.; Wang, X.; Usmani, S.; Mailankody, S.
Abstract Title:	Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
Meeting Title:	21st Annual Meeting and Exposition of the International Myeloma Society
Journal Title:	Clinical Lymphoma, Myeloma and Leukemia
Volume:	24
Issue:	Suppl. 2
Meeting Dates:	2024 Sep 25-28
Meeting Location:	Rio de Janeiro, Brazil
ISSN:	2152-2650
Publisher:	Elsevier Inc.
Date Published:	2024-09-01
Start Page:	S62
End Page:	S63
Language:	English
ACCESSION:	WOS:001325737900101
PROVIDER:	wos
DOI:	10.1016/S2152-2650(24)01941-4
Notes:	Meeting Abstract: P-038 -- Source: Wos